Kerstin Stenson to Chemoradiotherapy
This is a "connection" page, showing publications Kerstin Stenson has written about Chemoradiotherapy.
Connection Strength
1.198
-
Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7.
Score: 0.329
-
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
Score: 0.128
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.112
-
Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):512-22.
Score: 0.109
-
Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72.
Score: 0.092
-
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
Score: 0.088
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
Score: 0.085
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.080
-
Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9.
Score: 0.079
-
A nationwide analysis of salvage surgery for laryngeal cancer in the elderly. Head Neck. 2023 11; 45(11):2915-2924.
Score: 0.047
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.028
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.022